highconsequ
pathogen
continu
emerg
reemerg
global
lead
increas
public
health
concern
potenti
pandem
current
human
viral
diseas
outbreak
concern
includ
ongo
ebola
viru
diseas
epidem
west
africa
avian
influenza
caus
novel
influenza
viru
subtyp
china
enteroviru
infect
usa
topic
review
middl
east
respiratori
syndrom
mer
caus
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
infect
often
first
present
limit
diseas
outbreak
caus
rare
unknown
pathogen
increas
likelihood
signific
overlook
consequ
financi
resourc
rout
toward
infecti
diseas
deem
press
given
time
exampl
rare
agent
caus
human
infect
mani
year
erupt
outbreak
involv
thousand
rift
valley
fever
viru
case
ebola
viru
case
death
sinc
discoveri
late
case
death
decemb
march
agent
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
unexpectedli
eventu
caus
larg
epidem
case
death
seemingli
disappear
consequ
global
public
health
profession
challeng
ever
import
task
rapidli
develop
improv
method
infecti
diseas
detect
surveil
control
prevent
contain
widespread
effort
provid
swift
respons
emerg
diseas
mer
impress
spectrum
prevent
treatment
strategi
establish
vitro
rel
short
period
time
antivir
monoclon
polyclon
antibodi
vaccin
vitro
vivo
preclin
test
led
us
predica
scientif
commun
face
sar
epidem
laboratori
research
often
ineffici
translat
clinic
test
candid
therapeut
prophylact
delay
clinic
licensur
author
final
administr
outbreak
summar
evalu
progress
made
mer
vaccin
develop
provid
exampl
variou
challeng
encount
path
medic
countermeasur
licensur
mer
first
recogn
new
diseas
saudi
male
patient
respiratori
distress
admit
hospit
jeddah
saudi
arabia
june
soon
index
case
detect
peopl
identifi
suffer
ailment
major
mer
infect
report
western
asia
particular
saudi
arabia
unit
arab
emir
also
jordan
lebanon
kuwait
oman
qatar
yemen
later
mer
also
diagnos
europ
austria
franc
germani
greec
itali
netherland
uk
northern
africa
algeria
egypt
tunisia
northern
america
usa
southeastern
asia
malaysia
philippin
southern
asia
iran
among
peopl
travel
histori
western
asia
humantohuman
transmiss
merscov
estim
account
approxim
total
mer
case
origin
infect
merscov
unexplain
rest
case
risk
viru
transmiss
substanti
greater
index
case
secondari
case
increas
distribut
mer
case
within
arabian
peninsula
worrisom
instanc
past
year
concern
initi
mer
pandem
prompt
travel
restrict
makkah
saudi
arabia
million
muslim
pilgrim
prevent
ten
thousand
potenti
travel
make
religi
signific
hajj
journey
although
major
outbreak
mer
occur
direct
result
recent
hajj
trepid
remain
high
studi
reveal
older
men
individu
comorbid
condit
eg
diabet
hypertens
chronic
cardiac
lung
renal
diseas
greatest
risk
develop
fatal
mer
although
gender
bia
epidemiolog
unclear
whether
physiolog
genet
cultur
factor
play
role
increas
risk
toward
men
unknown
time
write
mer
case
confirm
includ
least
death
howev
increas
evid
subclin
infect
suggest
actual
number
human
mer
case
much
higher
current
confirm
number
etiolog
agent
mer
novel
betacoronaviru
rapidli
identifi
name
middl
east
respiratori
syndrom
coronaviru
merscov
merscov
origin
introduc
human
popul
mer
case
record
remain
determin
onehump
camel
camelu
dromedariu
current
suspect
anim
merscov
transmit
human
suspicion
stem
detect
antibodi
onehump
camel
herd
egypt
ethiopia
kenya
jordan
nigeria
oman
qatar
saudi
arabia
somalia
spain
sudan
tunisia
unit
arab
emir
merscov
genom
fragment
codingcomplet
genom
highli
similar
human
merscov
genom
detect
onehump
camel
merscov
directli
isol
sever
onehump
camel
grown
tissu
cultur
onehump
camel
experiment
infect
merscov
develop
minor
clinic
sign
respiratori
diseas
merscov
replic
upper
airway
serolog
evid
merscov
infect
found
peopl
potenti
exposur
infect
onehump
camel
three
serosurvey
therefor
zoonot
transmiss
onehump
camel
peopl
might
rare
event
howev
conclus
regard
caution
serosurvey
perform
publish
therefor
possibl
merscov
wide
distribut
among
onehump
camel
particular
genotyp
viru
evolv
allow
jump
human
popul
genom
studi
inde
reveal
presenc
sever
genet
variant
merscov
individu
onehump
camel
wherea
merscov
human
expos
onehump
camel
appear
infect
clonal
merscov
popul
onehump
camel
frequent
export
africa
arabian
peninsula
western
asia
anim
nativ
africa
could
transmit
merscov
onehump
camel
prior
export
figur
base
presenc
genom
fragment
genom
replic
virus
mani
betacoronavirus
seem
maintain
africa
europ
asia
phylogenet
highli
divers
bat
virus
includ
sarscov
virus
horsesho
bat
rhinolophu
spp
sever
virus
even
close
relat
merscov
detect
human
therefor
research
specul
merscov
could
batborn
viru
batorigin
hypothesi
base
betacoronaviru
phylogeni
receptor
usag
isol
merscov
one
individu
egyptian
tomb
bat
taphoz
perforatu
howev
studi
suggest
epidemiolog
evid
battohuman
battoonehump
camel
transmiss
merscov
figur
yet
gather
incub
period
day
mer
gener
present
human
lower
respiratori
infect
fever
often
chill
rigor
dri
product
cough
dyspnea
infrequ
patient
develop
chest
pain
headach
hemoptysi
myalgia
andor
sore
throat
sever
case
ill
quickli
progress
sever
atyp
pneumonia
acut
respiratori
distress
syndrom
sever
hypoxem
respiratori
failur
mer
often
includ
extrapulmonari
manifest
involv
circulatori
renal
andor
gastrointestin
system
abdomin
painnausea
diarrhea
emesi
rapidli
advanc
septic
shock
renal
failur
refractori
multipl
organ
failur
chest
xray
comput
tomographi
imag
often
reveal
subtl
extens
unilater
bilater
abnorm
consolid
increas
bronchovascular
mark
pleural
bronchial
wall
thicken
reticulonodular
airspac
opac
cardiomegali
clinic
chemistri
character
increas
alanin
transaminas
aspart
transaminas
concentr
patient
increas
llactat
dehydrogenas
concentr
case
low
albumin
hemoglobin
concentr
frequent
find
lymphopenia
thrombocytopenia
wherea
lymphocytosi
occur
rare
viral
load
usual
high
respiratori
tract
reach
genom
copiesml
may
low
absent
blood
moment
specif
antivir
agent
treatment
mer
avail
howev
sever
vitro
studi
identifi
drug
alreadi
clinic
use
potenti
could
repurpos
treatment
mer
drug
includ
inosin
monophosph
dehydrogenas
inhibitor
mycophenol
acid
use
treat
coronaviru
infect
pancoronaviru
inhibitor
target
membranebound
coronavir
rna
synthesi
guanosin
analog
ribavirin
use
treatment
hepat
c
respiratori
syncyti
viru
arenaviru
infect
inhibitor
estrogen
receptor
use
cancer
treatment
toremifen
citrat
inhibitor
dopamin
receptor
use
antipsychot
chlorpromazin
hydrochlorid
triflupromazin
hydrochlorid
kinas
signal
inhibitor
imatinib
mesyl
dasatinib
endocytosi
inhibitor
chlorpromazin
chloroquin
antidiarrh
agent
loperamid
proteas
inhibitor
lopinavir
transmembran
proteas
serin
proteas
inhibitor
camostat
unfortun
drug
evalu
anim
model
mer
except
part
due
absenc
anim
model
truli
reflect
human
diseas
see
absenc
approv
specif
antivir
agent
merscov
treatment
therefor
base
support
care
initi
laboratori
blood
test
chest
radiographi
patient
treat
broadspectrum
antibiot
control
often
nosocomi
secondari
bacteri
infect
howev
major
inpati
mer
case
escal
respiratori
failur
requir
intub
mechan
ventil
extracorpor
membran
oxygen
renal
replac
therapi
therefor
admiss
intens
care
unit
treatment
diseas
manag
mer
tremend
financi
burden
local
economi
event
pandem
financi
burden
may
prove
catastroph
especi
countri
limit
financi
resourc
base
small
number
analys
avail
outbreak
sar
tourco
hospit
franc
addit
hospit
administr
materi
resourc
cost
alon
approxim
us
per
inpati
due
need
increas
staff
contain
apparatus
person
protect
equip
requir
deal
highconsequ
pathogen
moreov
averag
mer
inpati
incur
ad
cost
prolong
intens
care
unit
stay
case
mechan
ventil
case
renal
replac
therapi
case
figur
world
bank
estim
global
econom
loss
trillion
us
dollar
event
sever
influenza
pandem
consid
mer
pathogen
pandem
potenti
global
cost
sar
epidem
alon
estim
us
billion
cost
develop
success
vaccin
approach
us
million
effect
vaccin
highconsequ
pathogen
potenti
save
time
cost
singl
year
use
estim
smallpox
vaccin
howev
true
costtobenefit
analysi
must
perform
determin
vaccin
develop
effort
provid
benefit
assum
mer
case
continu
rate
roughli
per
year
hospit
rate
addit
cost
per
inpati
approxim
us
averag
cumul
averag
cost
per
day
per
intervent
per
inpati
multipli
median
stay
per
respect
intervent
cost
develop
vaccin
would
justifi
within
year
figur
therefor
sustain
humantohuman
merscov
transmiss
occur
benefit
would
outweigh
cost
gener
vaccin
develop
worthwhil
pursuit
step
taken
expedit
approv
safe
effect
vaccin
emerg
pathogen
emerg
merscov
infect
spur
conglomer
tradit
novel
vaccin
strategi
success
hing
thorough
understand
genet
makeup
mechan
action
viru
merscov
member
genu
betacoronaviru
subfamili
coronavirina
nidoviral
coronavirida
like
nidovirus
merscov
positivesens
singlestrand
rna
linear
monopartit
genom
merscov
genom
encod
nonstructur
protein
major
structur
protein
accessori
structur
protein
tabl
nonstructur
protein
produc
proteolyt
cleavag
two
polyprotein
code
two
open
read
frame
major
compon
polymeras
complex
manag
replic
transcript
similar
mani
coronavirus
major
structur
protein
spike
protein
envelop
protein
e
membran
protein
nucleoprotein
n
primari
target
host
antibodymedi
immun
respons
focu
vaccin
develop
effort
surfac
glycoprotein
mer
coronavirion
mediat
attach
virion
target
cell
subsequ
entri
cell
fuse
viral
host
cell
membran
function
involv
two
distinct
domain
refer
respect
contain
host
cell
receptorbind
domain
engag
primari
merscov
cellsurfac
receptor
contain
epitop
crossreact
homolog
epitop
group
b
betacoronavirus
suggest
develop
gener
multival
betacoronaviru
vaccin
might
possibl
e
work
secur
structur
integr
virion
nucleoprotein
n
encapsid
viral
genom
rna
identif
natur
host
reservoir
emerg
human
pathogen
first
ideal
step
toward
prevent
transmiss
human
popul
could
educ
avoid
host
implement
proper
safeti
measur
come
contact
reservoir
contact
reservoir
host
avoid
eg
abund
econom
import
vaccin
host
may
straightforward
approach
prevent
hosttohuman
transmiss
addit
develop
anim
vaccin
may
ultim
cheaper
produc
faster
achiev
regulatori
hurdl
obtain
licensur
may
stringent
place
human
vaccin
develop
exampl
vaccin
wildlif
reservoir
rabi
reduc
human
case
usa
strategi
also
rel
new
pursuit
erad
tuberculosi
part
europ
vaccin
cattl
wildlif
unfortun
describ
natur
merscov
reservoir
merscov
transmiss
cycl
remain
defin
vaccin
onehump
camel
herd
could
feasibl
anim
often
keptraisedsold
human
wild
anim
could
identifi
rel
easili
howev
adult
onehump
camel
test
posit
merscov
despit
presenc
antimerscov
antibodi
preexist
neutral
antimerscov
antibodi
necessarili
protect
reinfect
merscov
observ
suggest
camel
vaccin
may
repeat
regularli
may
effect
probabl
even
unrealist
vaccin
bat
due
sheer
number
rel
small
depend
speci
often
quit
abund
anim
absenc
clearli
defin
zoonot
viru
ecolog
prompt
research
contempl
develop
human
vaccin
mer
tend
acut
yet
widespread
target
specif
human
popul
high
risk
infect
vaccin
logic
strategi
prevent
limit
infect
develop
distribut
vaccin
therefor
expedit
onehump
camel
handler
herder
healthcar
worker
veterinarian
travel
area
merscov
infect
preval
widespread
infect
throughout
gener
popul
expect
highrisk
popul
eg
age
peopl
person
cormorbid
target
vaccin
given
lack
suitabl
mer
anim
model
rel
clinic
data
merscov
patient
natur
success
immun
respons
merscov
infect
difficult
establish
serolog
pcrbase
assay
indic
mani
peopl
may
test
posit
merscov
despit
asymptomat
unknown
asymptomat
posit
individu
transient
expos
establish
carrier
state
develop
subclin
easili
control
infect
human
patient
data
avail
howev
faur
et
al
perform
ex
vivo
comparison
two
mer
patient
determin
immun
respons
infect
experi
base
bronchoalveolar
lavag
obtain
two
patient
identifi
one
succumb
mer
develop
respons
patient
lower
concentr
compar
patient
succumb
although
experi
involv
limit
sampl
size
data
support
necess
respons
zhao
et
al
investig
knockout
mice
evalu
immunolog
requir
clearanc
merscov
author
demonstr
mice
could
clear
merscov
rapidli
wildtyp
mice
similarli
tcell
bcell
knockout
mice
could
clear
viru
effici
control
mice
furthermor
vaccin
mice
reduc
viral
titer
serum
transfer
experi
provid
protect
homolog
merscov
infect
data
suggest
effici
bcell
respons
requir
protect
indirect
direct
b
tcell
function
respons
includ
criteria
candid
vaccin
evalu
clinic
data
becom
avail
correl
protect
difficult
establish
histor
first
vaccin
viral
pathogen
homotyp
liveattenu
virus
viru
isol
passag
anim
host
cell
line
nonvirul
liveattenu
strain
evolv
nonvirul
viru
use
vaccin
recent
method
develop
vaccin
genet
engin
viru
avirul
replic
incompet
replicationdefici
vaccin
viru
construct
gener
express
human
parainfluenza
human
respiratori
syncyti
viru
similarli
replicationdefici
adenovirus
develop
vaccin
ebola
viru
infect
phase
iia
clinic
trial
initi
evalu
efficaci
replic
modifi
vaccinia
ankara
mva
express
influenza
viru
protein
replic
mva
also
use
boost
effect
replicationdefici
adenovirusbas
vaccin
respons
main
concern
replic
live
viral
vaccin
possibl
dissemin
infect
immunosuppress
popul
eg
dissemin
vaccinia
viru
infect
heterotyp
vaccin
platform
possibl
revers
virul
case
homotyp
candid
new
method
replic
vaccin
develop
typic
incorpor
failsaf
mechan
mechan
includ
delet
gene
encod
protein
requir
viral
propag
introduct
suffici
number
genom
mutat
make
revers
extrem
unlik
instanc
almazan
et
al
engin
recombin
merscov
lack
e
open
read
frame
mer
candid
vaccin
howev
protect
efficaci
yet
demonstr
whole
inactiv
virion
prepar
often
provid
immunogen
replic
viral
vaccin
without
possibl
revers
virul
phenotyp
virion
kill
inactiv
chemic
radiolog
method
prior
use
vaccin
prepar
abl
replic
host
recipi
immun
system
still
mount
respons
present
antigen
although
exampl
inactiv
merscov
virion
yet
publish
inactiv
sarscov
particl
vaccin
test
minim
success
laboratori
mice
domest
ferret
use
inactiv
virion
prepar
prompt
sever
concern
one
concern
toxic
reagent
use
virion
inactiv
must
complet
remov
product
administr
anoth
concern
irradi
use
altern
toxic
agent
may
destroy
crucial
epitop
therefor
render
prepar
nonimmunogen
third
concern
inactiv
could
whatev
reason
incomplet
result
prepar
contain
fulli
virul
virus
concern
exacerb
increas
stigma
exist
among
gener
public
regard
vaccin
gener
chemic
addit
vaccin
prepar
particular
recombin
viral
vector
upgrad
replic
viral
vaccin
strategi
abil
optim
safeti
immunogen
via
bioengin
obviou
benefit
use
vaccin
platform
adenovirus
vesiculovirus
mva
foreign
gene
immunolog
interest
insert
heterotyp
viral
genom
proven
success
vaccin
recombin
viru
express
foreign
protein
stimul
protect
immun
respons
inocul
host
approach
also
use
success
develop
multival
vaccin
vaccin
confer
protect
multipl
variant
strain
pathogen
also
multipl
pathogen
simultan
recent
escriou
et
al
show
evid
bival
protect
laboratori
mice
measl
viru
sarscov
infect
construct
codon
optim
host
recognit
may
increas
attenu
protein
express
yield
greater
safeti
immunogen
vaccin
instanc
two
vaccin
mva
vaccin
adenovirusbas
vaccin
express
codonoptim
merscov
elicit
serum
antibodi
laboratori
mice
use
neutral
merscov
vitro
altern
method
immunogen
present
viral
vector
nanoparticl
protein
interest
formul
suitabl
adjuv
use
candid
vaccin
instanc
micellular
nanoparticl
merscov
trimer
express
surfac
novavax
inc
gaithersburg
md
usa
concentr
prepar
recombin
baculoviru
autographa
californica
multicapsid
nucleopolyhedroviru
acmnpv
express
merscov
acmnpv
gene
codonoptim
express
insect
cell
viru
propag
antibodi
induc
immun
laboratori
mice
dna
vaccin
typic
consist
viral
genom
segment
encod
neutral
epitop
contain
plasmid
combin
adjuv
administr
earli
fabric
fail
yield
protect
immun
respons
recent
studi
test
dna
vaccin
correct
shortcom
optim
constitu
deliveri
method
also
due
rel
simpl
lowcost
process
product
manufactur
dna
vaccin
competit
pursuit
one
dna
vaccin
quadrival
vaccin
hpv
infect
caus
type
wide
use
vaccin
program
numer
countri
unpublish
data
inovio
pharmaceut
suggest
strong
neutral
antibodi
elicit
possibl
multipl
strain
coverag
broad
tcell
respons
mice
immun
merscov
dna
vaccin
inovio
proprietari
technolog
involv
use
syncon
dna
vaccin
platform
inovio
proprietari
technolog
involv
use
syncon
dna
vaccin
platform
platform
incorpor
dna
multipl
strain
andor
antigen
dna
transfect
electropor
result
effici
deliveri
muscl
skin
cell
novel
vaccin
develop
strategi
interest
use
immunoinformat
predict
immunogen
part
viru
includ
vaccin
achiev
potent
relev
neutral
result
candid
vaccin
also
known
subunit
vaccin
current
mer
candid
vaccin
focu
receptorbind
domain
precis
sourc
adapt
immun
respons
would
gener
effect
neutral
antibodi
use
immunoinformat
sharmin
islam
chose
focu
epitop
found
rnadepend
rna
polymeras
rdrp
conserv
across
human
coronavirus
block
viral
replic
affect
rdrp
may
effect
vitro
method
yet
proven
effect
protect
host
infect
rna
viru
one
drawback
approach
rdrp
epitop
may
readili
detect
host
immun
system
rdrp
usual
major
structur
compon
virion
also
antigen
process
lead
wide
rang
tcell
bcell
immunoreact
epitop
therefor
focus
rdrp
epitop
would
provid
broad
effect
cellular
humor
respons
combin
aforement
immunoinformat
technolog
realist
approach
base
use
bcell
tcell
epitop
predict
base
viral
genom
sequenc
neutral
antibodi
merscov
structur
protein
primarili
believ
requir
inhibit
infect
addit
humor
immun
tcell
respons
consid
major
determin
protect
infecti
diseas
approach
use
bcell
tcell
epitop
use
research
terri
et
al
oani
et
al
develop
mer
candid
vaccin
approach
innov
actual
vivo
merscov
neutral
demonstr
date
evalu
candid
vaccin
highconsequ
viral
diseas
critic
depend
avail
anim
model
us
fda
anim
rule
permit
use
efficaci
data
anim
model
close
mimic
human
diseas
approv
medic
countermeasur
evalu
human
ethic
feasibl
due
high
lethal
viru
evalu
best
knowledg
fda
determin
mer
medic
countermeasur
develop
fall
anim
rule
howev
identif
develop
suitabl
anim
model
human
diseas
mani
challeng
caveat
upon
exposur
merscov
anim
display
respiratori
distress
fever
tussi
dyspnea
gastrointestin
sign
vomit
diarrhea
renal
failur
sinc
merscov
first
identifi
sever
group
attempt
develop
mer
anim
model
laboratori
mice
syrian
hamster
mesocricetu
auratu
domest
ferret
mustela
putoriu
furo
evalu
potenti
model
medic
countermeasur
screen
understand
pathogen
mechan
initi
experi
includ
screen
wildtyp
balbc
knockout
laboratori
mice
suscept
merscov
infect
develop
diseas
howev
mice
develop
clinic
sign
diseas
infecti
viru
could
recov
zhao
et
al
overcam
hurdl
transduc
balbc
mice
human
use
adenoviru
construct
transduc
mice
permiss
merscov
infect
demonstr
minim
weight
loss
howev
candid
medic
countermeasur
mous
model
evalu
compar
chang
viral
titer
lung
day
postinocul
treat
untreat
anim
transductionbas
model
may
also
prove
quit
variabl
due
infect
efficaci
transduc
vector
nonhuman
primat
rhesu
monkey
macaca
mulatta
crabeat
macaqu
macaca
fasciculari
grivet
chlorocebu
aethiop
common
marmoset
callithrix
jacchu
frequent
use
develop
anim
model
human
viral
diseas
immunolog
similar
human
merscov
inocul
rhesu
monkey
gave
vari
result
lead
diseas
limit
similar
human
diseas
instanc
studi
yao
et
al
reveal
intratrach
inocul
rhesu
monkey
merscov
result
nonleth
diseas
limit
patholog
could
observ
day
postinocul
de
wit
et
al
describ
studi
nonhuman
primat
follow
inocul
combin
intratrach
intranas
oral
conjunctiv
rout
rhesu
monkey
euthan
day
postinocul
merscov
evalu
virolog
immunolog
histopatholog
chang
euthanasia
time
point
anim
sign
pneumonia
replic
viru
could
demonstr
tissu
mucou
membran
quantit
pcr
howev
inher
serialsampl
design
diseas
progress
induc
viral
infect
truncat
limit
data
glean
studi
followup
studi
falzarano
et
al
demonstr
administr
antiinflammatori
immunomodul
ribavirin
reduc
viral
burden
lessen
diseas
sever
follow
intratrach
intranas
oral
ocular
challeng
merscov
xray
radiograph
indic
lung
infiltr
day
postinocul
suggest
virusinduc
lung
diseas
howev
two
studi
includ
mockinocul
control
demonstr
observ
clinic
sign
due
gener
inflamm
inocul
handl
procedur
recent
falzarano
et
al
describ
intratrach
inocul
common
marmoset
merscov
result
partial
lethal
diseas
howev
anim
receiv
larg
volum
bolu
merscov
ml
intratrach
disproportion
base
small
lung
volum
ml
common
marmoset
johnson
rf
unpublish
observ
measur
comput
tomographi
n
addit
experi
includ
anim
receiv
control
inocula
therefor
extent
virusinduc
patholog
compar
patholog
due
anim
manipul
remain
unclear
overal
suitabl
nonhuman
primat
model
human
mer
still
lack
onehump
camel
reservoir
merscov
see
vaccin
merscov
infect
may
provid
intervent
opportun
figur
inde
three
onehump
camel
inocul
intranas
intratrach
conjunctiv
rout
merscov
develop
benign
clinic
sign
shed
larg
quantiti
viru
upper
respiratori
tract
comparison
drawn
uniformli
lethal
anim
model
onehump
camel
model
would
interest
mer
anim
model
base
onehump
camel
mani
challeng
larg
size
anim
rel
scarciti
western
world
classif
merscov
risk
group
pathogen
requir
biosafeti
level
contain
limit
number
facil
could
perform
studi
colorado
state
univers
kansa
state
univers
unit
state
depart
agricultur
ame
ia
usa
commonwealth
scientif
industri
research
organis
commonli
known
csiro
clayton
south
australia
lab
could
handl
larg
anim
altern
use
camelid
alpaca
vicugna
paco
guanaco
lama
guanico
llama
llama
glama
vicugna
vicugna
camelid
smaller
may
easier
obtain
bactrian
camel
camelu
bactrianu
camel
big
onehump
camel
rarer
howev
consequ
merscov
inocul
anim
requir
evalu
recent
emerg
merscov
reemerg
sever
highconsequ
pathogen
recent
year
spur
retool
current
vaccin
strategi
develop
procedur
mani
current
mer
vaccin
develop
strategi
base
sar
research
howev
year
sinc
first
descript
sar
vaccin
prevent
sarscov
infect
approv
fact
bode
well
research
clinician
research
defici
mer
candid
vaccin
emphasi
place
improv
translat
research
licensur
procedur
anim
model
develop
emerg
pathogen
transient
outbreak
infecti
diseas
mer
appear
subsid
rel
quickli
justif
fund
research
effort
vaccin
develop
alway
straightforward
unfortun
vaccin
develop
often
seem
reactionari
rather
prospect
instanc
vaccin
develop
ebola
viru
diseas
overal
nich
activ
current
outbreak
affect
thousand
peopl
rare
emerg
pathogen
analys
vaccin
develop
must
calcul
base
limit
knowledg
pandem
andor
reemerg
potenti
exampl
merscov
show
even
spars
econom
data
avail
cost
estim
shown
figur
warrant
mer
vaccin
develop
econom
loss
even
small
infecti
diseas
outbreak
far
outweigh
cost
associ
vaccin
develop
howev
faster
method
move
candid
vaccin
laboratori
bench
clinic
essenti
ondemand
acceler
strategi
current
evalu
support
effort
advanc
light
ebola
viru
diseas
outbreak
ad
effort
acceler
clinic
trial
regulatori
file
licensur
approv
affect
vaccin
develop
highconsequ
pathogen
futur
compani
like
novavax
inovio
pharmaceut
advantag
establish
pipelin
develop
approv
mer
vaccin
mer
wildlif
vaccin
target
onehump
camel
also
evalu
consid
encourag
rate
new
technolog
develop
emerg
pathogen
treatment
strategi
licens
mer
vaccin
feasibl
within
year
appropri
mer
anim
model
becom
avail
typic
timelin
vaccin
develop
manufactur
prior
regulatori
submiss
approxim
year
figur
